Gleave ME - Search Results

1

Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.

Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, Cox ME, Huntsman DG. Rajput AB, et al. Among authors: gleave me. J Clin Pathol. 2007 Nov;60(11):1238-43. doi: 10.1136/jcp.2006.043810. Epub 2007 Jan 26. J Clin Pathol. 2007. PMID: 17259299 Free PMC article.

2

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.

Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Gleave ME, et al. J Urol. 1996 Jan;155(1):213-9. J Urol. 1996. PMID: 7490838 Clinical Trial.

3

Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer.

Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Kinahan J, Sullivan LD. Gleave ME, et al. Semin Urol Oncol. 1996 May;14(2 Suppl 2):39-45; discussion 46-7. Semin Urol Oncol. 1996. PMID: 8725890 Review.

4

Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors.

Leung SY, Jackson J, Miyake H, Burt H, Gleave ME. Leung SY, et al. Among authors: gleave me. Prostate. 2000 Jul 1;44(2):156-63. doi: 10.1002/1097-0045(20000701)44:2<156::aid-pros8>3.0.co;2-8. Prostate. 2000. PMID: 10881025

5

Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.

Gleave ME, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Gleave ME, et al. Urology. 2000 Aug 1;56(2):289-94. doi: 10.1016/s0090-4295(00)00627-0. Urology. 2000. PMID: 10925096

6

Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.

Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME. Leung S, et al. Among authors: gleave me. Int J Cancer. 2001 Mar 15;91(6):846-50. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1131>3.0.co;2-y. Int J Cancer. 2001. PMID: 11275990

7

Inflammatory pseudotumor of the urinary bladder: a report of five cases and review of the literature.

Poon KS, Moreira O, Jones EC, Treissman S, Gleave ME. Poon KS, et al. Among authors: gleave me. Can J Urol. 2001 Dec;8(6):1409-15. Can J Urol. 2001. PMID: 11788019 Review.

8

Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy.

July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. July LV, et al. Among authors: gleave me. Prostate. 2002 Feb 15;50(3):179-88. doi: 10.1002/pros.10047. Prostate. 2002. PMID: 11813210

9

Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience.

Hurtado-coll A, Goldenberg SL, Klotz L, Gleave ME. Hurtado-coll A, et al. Among authors: gleave me. Urology. 2002 Sep;60(3 Suppl 1):45-51; discussion 51. doi: 10.1016/s0090-4295(02)01570-4. Urology. 2002. PMID: 12231047 Review.

10

Intermittent androgen suppression in prostate cancer: the Canadian experience.

Hurtado-Coll A, Goldenberg SL, Gleave ME, Klotz L. Hurtado-Coll A, et al. Among authors: gleave me. Urology. 2002 Sep;60(3 Suppl 1):52-6; discussion 56. doi: 10.1016/s0090-4295(02)01572-8. Urology. 2002. PMID: 12231049 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

667 results

Search Page

Filters